Navigation Links
SkylineDx Presented New Algorithm Demonstrating Ability to Successfully Identify Gene Sets that are Informative of Cancer Treatment Specific Survival

ROTTERDAM, Netherlands and LAGUNA HILLS, Calif., April 10, 2017 /PRNewswire/ -- SkylineDx announced that they had developed TOPSPIN (Treatment Outcome Prediction using Similarity between PatIeNts) algorithm for identifying subgroups of patients with multiple myeloma (MM) who are likely to benefit from a new anti-cancer treatment. In the presentation at the BioSB 2017 conference in Lunteren, the Netherlands, researchers described how they used SkylineDx's MMprofiler™ technology and data to develop TOPSPIN, a new computational algorithm to identify gene sets that predict if a patient is likely to survive longer when receiving a treatment of interest versus alternative treatments.

"The wide variance in response rates to multiple myeloma therapies makes it critical to select the right treatment at the time of diagnosis. This requires discovery of predictive biomarkers, such as a gene expression signature, that can predict survival based on which treatment patients receive," said Joske Ubels, a PhD candidate at SkylineDx, Erasmus Medical Center and the University Medical Center Utrecht. "Finding predictive biomarkers is a particularly difficult machine learning challenge, because currently it is unknown which patients have a survival benefit from a treatment, and which patients have no survival benefit. Moreover, the large amounts of gene expression data generated using platforms such as the MMprofiler poses a computational challenge. To overcome this, we developed TOPSPIN, a new smart search strategy, which leverages biological knowledge combined with high performance computing. We can use the TOPSPIN algorithm to identify gene sets that inform treatment-specific survival, enabling categorization of patients into two subgroups, one of which experiences significantly greater benefit from the treatment of interest than the other class."

In her BioSB presentation, Ms. Ubels demonstrated the utility of the TOPSPIN method in a MM dataset, in which 910 patients either received (n = 396) or did not receive bortezomib therapy (n = 514). She and her colleagues defined gene sets using the Gene Ontology (GO) annotation, which provides functionally related groups of genes. They then tested random gene sets with the same structure as the GO sets. TOPSPIN successfully identified subsets of patients with longer PFS when treated with Bortezomib.

"The new data establish proof of principle for the TOPSPIN algorithm," commented Dharminder S. Chahal, Chief Executive Officer of SkylineDx. "We plan to test TOPSPIN on other datasets to predict response to different treatments in various cancer types. We thus hope to find other gene sets associated with response to specific anticancer agents, knowledge that can help guide therapeutic decision-making."

About Multiple Myeloma  
Multiple myeloma (MM) is a cancer that arises from plasma cells, a type of white blood cell made in the bone marrow. In patients with MM, the plasma cells become abnormal, multiply uncontrollably, and release only one type of antibody – known as M-protein – which has no useful function. It is often through the measurement of M-protein that MM is diagnosed and monitored. Most medical problems related to MM are caused by the build-up of abnormal plasma cells in the bone marrow and the presence of the M-protein in the blood or urine. The most common symptoms of MM include bone pain, recurring infection, kidney damage, and fatigue. According to the World Cancer Research Fund International, an estimated 114,000 people around the world are diagnosed with MM annually, and the disease represents 0.8% of all cancers globally.

For more information about MM, visit (information available in Dutch only),,,,, and

About MMprofiler™ 
MMprofiler SKY92 prognostic gene signature assesses risk by measuring the activity of 92 MM-related genes that comprise SKY92, the novel, proprietary gene signature. The lead product of SkylineDx, MMprofiler is proven superior to the biomarkers currently used to risk stratify newly diagnosed and relapsed multiple myeloma patients into a "high" or "standard" risk category.1 Included in a growing number of international treatment guidelines, MMprofiler is CE-IVD registered in Europe and will be coming soon as a laboratory-developed test (LDT) in the United States. For more information, please visit

About SkylineDx
SkylineDx is a commercial-stage biotech company based in Rotterdam, the Netherlands. Originally a spin-off of the Erasmus Medical Center in Rotterdam, the company specializes in the development and marketing of innovative gene signature-based prognostic tests to assist healthcare professionals in making personalized treatment decisions for individual patients. These tests are designed to accurately determine the type or status of the disease or to predict a patient's response to a specific treatment. Based on the test results, healthcare professionals can tailor the treatment to the individual patient. MMprofiler is the company's lead product. To learn more, please visit

1 Van Beers EH, et al. SKY92 GEP, iFISH, and ISS comparisons for risk stratification in multiple myeloma. Poster p661 presented at 2015 European Hematology Association Congress.  

To view the original version on PR Newswire, visit:

SOURCE SkylineDx
Copyright©2017 PR Newswire.
All rights reserved

Related biology technology :

1. OncoGenex Pharmaceuticals, Inc. Announces Phase 2 Apatorsen Data for Two Clinical Trials Presented at the American Society of Clinical Oncology (ASCO) 2017 Genitourinary Cancers Symposium
2. ProclaRx Presented Technology and Business Updates at Medtech Showcase in San Francisco
3. Clinical Utility of Biocepts Liquid Biopsy Platform Demonstrated in Study Results Presented at the 2016 San Antonio Breast Cancer Symposium
4. ACEA Biosciences Announces Data Presentation at WCLC 2016 Conference: New AC0010 Data to Be Presented
5. A Novel Approach to Alzheimer’s Drug Therapy, Phase 2a Clinical Trial Results of T3D-959 to be Presented by T3D Therapeutics at CTAD
6. CTI BioPharma Announces Phase 3 Data from the PERSIST-2 Trial of Pacritinib to be Presented in Late-Breaking Session at ASH Annual Meeting
7. Immigrant Journey Awards Presented to Outstanding North Texas Immigrants
8. Hydrogel Talks on Medical, Industrial, and Emerging Applications Presented by RadTech Non Profit
9. Data Demonstrating Extremely High Sensitivity of Biocepts Blood-Based Liquid Biopsy in Detecting Lung Cancer Mutations Presented at UCSD Moores Cancer Center Translational Oncology Symposium
10. New NX Prenatal Preterm Birth Risk Biomarker Data Presented at Society for Maternal Fetal Medicine Annual Meeting
11. Combined Technologies of ViveBio and ZeptoMetrix Featured in Study Presented at HEP DART 2015
Post Your Comments:
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... While art ... are much more closely connected than one might think. A Mesh Is Also ... open at the University City Science Center’s Esther Klein Gallery (EKG) on August 17 ...
(Date:8/16/2017)... , Aug. 16, 2017  This year,s edition of the Inc. ... in life sciences workforce solutions, has made the list for the third ... recognizes the nation,s fastest-growing private companies based on a set of quantitative ... which includes the fastest-growing companies in the Bay State ... Inc. 5000 ...
(Date:8/15/2017)... , ... August 15, 2017 , ... Kapstone Medical ... 10 years of successes helping medical technology companies and inventors develop and safeguard their ... renowned full-service national engineering firm with a portfolio of clients in the United States ...
(Date:8/15/2017)... (PRWEB) , ... August 15, 2017 , ... Any expert ... that has compromised these disciplines for more than half a century. Despite their ... counted. It is widely known that molecular tags developed for this purpose also ...
Breaking Biology Technology:
(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
(Date:4/4/2017)... 2017   EyeLock LLC , a leader of ... States Patent and Trademark Office (USPTO) has issued U.S. ... of an iris image with a face image acquired ... company,s 45 th issued patent. ... given the multi-modal biometric capabilities that have recently come ...
(Date:3/30/2017)... 2017  On April 6-7, 2017, will host ... hackathon at Microsoft,s headquarters in Redmond, ... on developing health and wellness apps that provide a ... Genome is the first hackathon for personal genomics ... companies in the genomics, tech and health industries are ...
Breaking Biology News(10 mins):